Theris Medical Patch

This is the first biopharmaceutical innovation created by the team at TauTona Group and based upon technology developed over years of research in Dr. Gurtner’s lab at Stanford University. In his research, Dr. Gurtner identified that deferoxamine, a drug sickle cell patients already use intravenously for removing excess iron in the blood could have a favorable effect on healing sickle cell leg ulcers if applied topically. TauTona licensed the technology to transition the novel wound care treatment from the lab to the clinic. FDA Orphan Drug Designation was granted and we are starting clinical trials in Q3 2020. To learn more, visit therismedical.com.